Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Bismuth subcitrate potassium is a colloid used for the treatment of peptic ulcer and gastro-esophageal reflux disease (GERD). A medication used to treat digestive disorders associated with open sores and heartburn.
- Mechanism
- Curator reviewed
Colloidal bismuth subcitrate is very effective in the treatment of gastroduodenal disorders and appears to act via several mechanisms. It has little acid-neutralizing effect and does not affect acid secretion. It is uncertain whether it affects pepsin secretion, but it does inhibit peptic activity. It causes an increase in mucus glycoprotein secretion and may also bind to the gastric mucus layer to act as a diffusion barrier to HCl. It accelerates ulcer healing and causes an accumulation of epidermal growth factor around the ulcer. In addition, it has a cytoprotective effect and increases mucosal secretion of prostaglandins and bicarbonate. It has bactericidal effects against Helicobacter pylori (which is associated with gastritis and peptic ulcers). It also prevents adhesion of H. pylori to epithelial cells and can inhibit enzymes secreted by H. pylori, such as proteases, lipases, glycosidases, and phospholipases.
- Primary indication
- For the treatment of peptic ulcer and gastro-oesophageal reflux disease (GORD).Curator reviewed · 11 structured indications
- Formula / weight
- C12H8BiK5O14 · 780.654 g/mol (avg)
- First approval
- Canada, 2023 · United States, 2007
- Brand names
- Pylera
Resolves to
YDDTTXDPCSCLKY-UHFFFAOYSA-HSMILES[K+].[K+].[K+].[K+].[K+].[Bi+3].[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=O.[O-]C(=O)CC([O-])(CC([O-])=O)C([O-])=OWhat you can answer from here — as of August 30, 2026
Which drugs share a target with Bismuth subcitrate potassium, and which of those have an active Phase 3 trial?